A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 413 participants.
Also called NCT04153929
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 413 participants
- Sponsor
- Registry
-
NCT04153929 -
2019-002390-60
-
- Other papers using this trial's data
- Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Canada, Czechia, Germany, Hungary, New Zealand, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04153929. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-30 (actual); primary completion 2021-10-08 (actual). Results posted on 2022-11-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- BI 456906
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct04153929- Content hash
509ce21145642ee587b6f91a9021bfe5bcb8cd2951e735149a0b6595cdf00013